Angion Biomedica Corp.

1.03-0.0100-0.96%Vol 112.76K1Y Perf -89.93%
Aug 16th, 2022 16:00 DELAYED
BID1.02 ASK1.09
Open1.05 Previous Close1.04
Pre-Market- After-Market1.03
 - -  - -%
Target Price
1.50 
Analyst Rating
Hold 3.00
Potential %
45.63 
Finscreener Ranking
★★★★+ —    57.54
Insiders Trans % 3/6/12 mo.
100/100/-11 
Value Ranking
★★★★     56.18
Insiders Value % 3/6/12 mo.
100/100/4 
Growth Ranking
★★★     52.47
Insiders Shares Cnt. % 3/6/12 mo.
100/100/30 
Income Ranking
 —    -
Price Range Ratio 52W %
0.38 
Earnings Rating
Market Cap30.86M 
Earnings Date
11th Aug 2022
Alpha-0.13 Standard Deviation0.24
Beta0.80 

Today's Price Range

1.010.00

52W Range

0.982113.66

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-2.83%
3 Months
-15.57%
6 Months
-51.42%
1 Year
-89.93%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANGN1.03-0.0100-0.96
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
98.50
-114.40
-111.50
-1 185.80
-51.82
RevenueValueIndustryS&P 500US Markets
29.05M
0.97
150.12
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.46-0.3034.78
Q01 2022-0.44-0.48-9.09
Q04 2021-0.590.58198.31
Q03 2021-0.73-0.5327.40
Q02 2021-0.69-0.5815.94
Q01 2021-0.62-0.94-51.61
Q04 2020-1.30-1.90-46.15
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.46
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume112.76K
Shares Outstanding29.96K
Shares Float25.48M
Trades Count401
Dollar Volume116.34K
Avg. Volume111.86K
Avg. Weekly Volume79.80K
Avg. Monthly Volume96.45K
Avg. Quarterly Volume159.33K

Angion Biomedica Corp. (NASDAQ: ANGN) stock closed at 1.03 per share at the end of the most recent trading day (a -0.96% change compared to the prior day closing price) with a volume of 112.76K shares and market capitalization of 30.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Angion Biomedica Corp. CEO is Jay Venkatesan.

The one-year performance of Angion Biomedica Corp. stock is -89.93%, while year-to-date (YTD) performance is -64.48%. ANGN stock has a five-year performance of %. Its 52-week range is between 0.98206 and 13.66, which gives ANGN stock a 52-week price range ratio of 0.38%

Angion Biomedica Corp. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 0.46, a price-to-sale (PS) ratio of 1.07, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -29.14%, a ROC of -37.87% and a ROE of -40.25%. The company’s profit margin is -51.82%, its EBITDA margin is -111.50%, and its revenue ttm is $29.05 Million , which makes it $0.97 revenue per share.

Of the last four earnings reports from Angion Biomedica Corp., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Angion Biomedica Corp.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Angion Biomedica Corp. is Hold (3), with a target price of $1.5, which is +45.63% compared to the current price. The earnings rating for Angion Biomedica Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Angion Biomedica Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Angion Biomedica Corp. has a Sell technical analysis rating based on Technical Indicators (ADX : 6.03, ATR14 : 0.09, CCI20 : -65.15, Chaikin Money Flow : -0.27, MACD : -0.06, Money Flow Index : 61.59, ROC : -4.59, RSI : 34.00, STOCH (14,3) : 25.00, STOCH RSI : 0.43, UO : 33.34, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Angion Biomedica Corp. in the last 12-months were: Allen R. Nissenson (Buy at a value of $10 925), Gregory S. Curhan (Buy at a value of $9 480), Itzhak D. Goldberg (Sold 267 882 shares of value $1 039 262 ), Jay Venkatesan (Buy at a value of $1 147 787), Jennifer J. Rhodes (Sold 1 744 shares of value $11 290 ), John F. Neylan (Sold 1 862 shares of value $12 925 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
2 (50.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (100.00 %)
2 (50.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Moderate Buy
2.00
Strong Buy
1.00

Angion Biomedica Corp.

Angion Biomedica Corp was incorporated in the State of Delaware on April 6. 1998. It is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body's protective, reparative and regenerative systems. It is developing therapeutics for both orphan indications and large clinical markets of unmet medical need.

CEO: Jay Venkatesan

Telephone: +1 516 326-1200

Address: 51 Charles Lindbergh Boulevard, Uniondale 11553, NY, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

66%34%

Bearish Bullish

64%36%


News

Stocktwits